Principles of selecting cost-effectiveness thresholds in price-taker countries
Expert Review of Pharmacoeconomics & Outcomes Research · 09.08.2026 · 26 (7) · 843-850
DOI: 10.1080/14737167.2026.2715977 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 12.08.2026. Verfasst von Zoltán Kaló und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Drug Industry, Drug Costs. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION: Countries with relatively small market size lack the bargaining power to influence the prices set by pharmaceutical companies, so they function as price-taker rather than price-maker. For price-taker countries, carefully established cost-effectiveness thresholds (CETs) are essential tools to assess local economic value of new medicines. AREAS COVERED: This perspective paper provides an overview of how pharmaceutical price-taker countries may reconsider their CETs. Key aspects of selecting appropriate CETs in price-taker countries include i) the methodology for establishing the main CETs, ii) the selection of factors to modify the baseline CET, if higher spending for one unit of health gain seems justified, and iii) the process of using CETs in policy decisions. EXPERT OPINION: Many academic approaches described in scientific articles are not implemented; the majority of countries establish or make changes in their CETs without strong theoretical foundation. In the next years. several price-taker countries will introduce or update CETs. Lower-income countries, who linked their CETs to the GDP per capita and whose economy has been growing significantly, may reduce their baseline thresholds. There will be significant pressure on higher-income countries to increase their CETs, who did not adjust their CETs for economic growth and/or inflation in recent years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
- Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary.
- Syreon Research Institute, Budapest, Hungary.
- Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
- Institute for Medical Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
- Erasmus Centre for Health Economics Rotterdam, Erasmus University Rotterdam, Rotterdam, The Netherlands.
ORCID-Profile: Tomáš Tesař, Bertalan Németh
Zitieren
APA
Kaló, Z., Rutten-van Mölken, M., Aas, E., Salcher-Konrad, M., Tesař, T., Belleman, T., Huic, M., Masaryková, L., Koblišková, Z., Hendrickx, A., Németh, B., Fasseeh, A. N., & Uyl-de Groot, C. (2026). Principles of selecting cost-effectiveness thresholds in price-taker countries. Expert Review of Pharmacoeconomics & Outcomes Research, 26(7), 843-850. https://doi.org/10.1080/14737167.2026.2715977
Vancouver
Kaló Z, Rutten-van Mölken M, Aas E, Salcher-Konrad M, Tesař T, Belleman T, et al. Principles of selecting cost-effectiveness thresholds in price-taker countries. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(7):843-850. doi:10.1080/14737167.2026.2715977
BibTeX
@article{Kal2026,
author = {Kaló, Zoltán and Rutten-van Mölken, Maureen and Aas, Eline and Salcher-Konrad, Maximilian and Tesař, Tomáš and Belleman, Tom and Huic, Mirjana and Masaryková, Lucia and Koblišková, Zuzana and Hendrickx, Anne and Németh, Bertalan and Fasseeh, Ahmad Nader and Uyl-de Groot, Carin},
title = {Principles of selecting cost-effectiveness thresholds in price-taker countries},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
volume = {26},
number = {7},
pages = {843--850},
doi = {10.1080/14737167.2026.2715977}
}
EUVIMED